ACADIA Pharmaceuticals Inc — Quarterly Financial Statistics (NASDAQ:ACAD) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics Dividends

Quarterly Annual

Cash from operating activities 63.25 M40.38 M20.32 M63.96 M74.29 M-48.73 M 109.84 M Cash from investing activities 82.46 M-122.15 M124.05 M43.29 M79.35 M55.87 M 302.56 M Cash from financing activities 268 K1.97 M1.84 M15.96 M9.42 M22.67 M 49.88 M Free cash flow 63.25 M40.38 M-78.52 M63.96 M74.29 M-48.73 M 11 M

ACADIA Pharmaceuticals Inc

Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.

Nouvelles

Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs (ACAD)

ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth

Jefferies relève l’objectif de cours d’Acadia Pharmaceuticals

Jefferies raises Acadia Pharmaceuticals stock price target on guidance

Citizens relève l’objectif de cours d’Acadia Pharmaceuticals sur les perspectives de croissance

Citizens raises Acadia Pharmaceuticals price target on growth outlook

ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call Transcript

ACADIA Pharmaceuticals Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:ACAD) 2026-02-25

Acadia Pharmaceuticals (ACAD) Q4 Earnings Top Estimates

ACADIA Q4 2025 slides: $1B revenue milestone as both drugs post double-digit growth

Résultats d’Acadia en vue : croissance attendue malgré la pression

Wolfe Research initie la couverture d’Acadia avec une note surperformance